|
1
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burnett JC and Rossi JJ: RNA-based
therapeutics: current progress and future prospects. Chem Biol.
19:60–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tuerk C and Gold L: Systematic evolution
of ligands by exponential enrichment: RNA ligands to bacteriophage
T4 DNA polymerase. Science. 249:505–510. 1990. View Article : Google Scholar
|
|
4
|
Sefah K, Shangguan D, Xiong X, O’Donoghue
MB and Tan W: Development of DNA aptamers using Cell-SELEX. Nature
Protoc. 5:1169–1185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gan HK, Kaye AH and Luwor RB: The EGFRvIII
variant in glioblastoma multiforme. J Clin Neurosci. 16:748–754.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu W, Fu Y, Xu S, et al: c-Met expression
is associated with time to recurrence in patients with glioblastoma
multiforme. J Clin Neurosci. 18:119–121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chu TC, Twu KY, Ellington AD and Levy M:
Aptamer mediated siRNA delivery. Nucleic Acids Res. 34:e732006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McNamara JO II, Andrechek ER, Wang Y, et
al: Cell type-specific delivery of siRNAs with aptamer-siRNA
chimeras. Nat Biotechnol. 24:1005–1015. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dassie JP, Liu XY, Thomas GS, et al:
Systemic administration of optimized aptamer-siRNA chimeras
promotes regression of PSMA-expressing tumors. Nat Biotechnol.
27:839–849. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou J, Li H, Zhang J, Piotr S and Rossi
J: Development of cell-type specific anti-HIV gp120 aptamers for
siRNA delivery. J Vis Exp. 52:29542011.PubMed/NCBI
|
|
11
|
Wheeler LA, Trifonova R, Vrbanac V, et al:
Inhibition of HIV transmission in human cervicovaginal explants and
humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest.
121:2401–2412. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou J, Swiderski P, Li H, et al:
Selection, characterization and application of new RNA HIV gp 120
aptamers for facile delivery of Dicer substrate siRNAs into HIV
infected cells. Nucleic Acids Res. 37:3094–3109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thiel KW, Hernandez LI, Dassie JP, et al:
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells
using RNA aptamers. Nucleic Acids Res. 40:6319–6337.
2012.PubMed/NCBI
|
|
14
|
Tan Y, Shi YS, Wu XD, et al: DNA aptamers
that target human glioblastoma multiforme cells overexpressing
epidermal growth factor receptor variant III in vitro. Acta
Pharmacol Sin. 34:1491–1498. 2013. View Article : Google Scholar
|
|
15
|
Zhan Y and O’Rourke DM: SHP-2-dependent
mitogen-activated protein kinase activation regulates EGFRvIII but
not wild-type epidermal growth factor receptor phosphorylation and
glioblastoma cell survival. Cancer Res. 64:8292–8298. 2004.
View Article : Google Scholar
|
|
16
|
Nicholas MK, Lukas RV, Chmura S, Yamini B,
Lesniak M and Pytel P: Molecular heterogeneity in glioblastoma:
therapeutic opportunities and challenges. Semin Oncol. 38:243–253.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shangguan D, Cao ZC, Li Y and Tan W:
Aptamers evolved from cultured cancer cells reveal molecular
differences of cancer cells in patient samples. Clin Chem.
53:1153–1155. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang YF, Shangguan D, Liu H, et al:
Molecular assembly of an aptamer-drug conjugate for targeted drug
delivery to tumor cells. Chembiochem. 10:862–868. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Y, Sefah K, Liu H, Wang R and Tan W:
DNA aptamer-micelle as an efficient detection/delivery vehicle
toward cancer cells. Proc Natl Acad Sci USA. 107:5–10. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang K, Sefah K, Tang L, et al: A novel
aptamer developed for breast cancer cell internalization.
ChemMedChem. 7:79–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thiel KW and Giangrande PH: Intracellular
delivery of RNA-based therapeutics using aptamers. Ther Deliv.
1:849–861. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McCarty JH: Glioblastoma resistance to
anti-VEGF therapy: has the challenge been MET? Clin Cancer Res.
19:1631–1633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peruzzi B and Bottaro DP: Targeting the
c-Met signaling pathway in cancer. Clin Cancer Res. 12:3657–3660.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pillay V, Allaf L, Wilding AL, et al: The
plasticity of oncogene addiction: implications for targeted
therapies directed to receptor tyrosine kinases. Neoplasia.
11:448–458, 2 p following 458. 2009.PubMed/NCBI
|
|
26
|
Huang PH, Mukasa A, Bonavia R, et al:
Quantitative analysis of EGFRvIII cellular signaling networks
reveals a combinatorial therapeutic strategy for glioblastoma. Proc
Natl Acad Sci USA. 104:12867–12872. 2007. View Article : Google Scholar : PubMed/NCBI
|
